Clinical Trial Details
| Trial ID: | L0184 |
| Source ID: | NCT05153174 |
| Associated Drug: | Sulforaphane |
| Title: | Study of Sulphoraphane in Chronic Kidney Disease |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT05153174/results |
| Conditions: | Chronic Kidney Disease stage3|Chronic Kidney Disease stage4 |
| Interventions: | DRUG: Sulforaphane |
| Outcome Measures: | Primary: Area Under the Concentration-Time Curve (AUC 0-8h) in Plasma, Sulforaphane drug levels will be measured in plasma at 0, 1, 2, 4, and 8 hours., prior to initial dose on day 7 and 1, 2, 4, and 8 hours post-dose|Area Under the Concentration-Time Curve (AUC 0-8h) in Urine, Sulforaphane drug levels will be measured in urine at 0, 1, 2, 4, and 8 hours., prior to initial dose on day 7 and 1, 2, 4, and 8 hours post-dose|Number of Participants With an Adverse Event, Adverse Event is any side effect outside of the subject's baseline., day 7 | |
| Sponsor/Collaborators: | Sponsor: University of Rochester | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1 |
| Enrollment: | 18 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2022-05-02 |
| Completion Date: | 2023-06-08 |
| Results First Posted: | 2024-08-12 |
| Last Update Posted: | 2024-08-12 |
| Locations: | University of Rochester Medical Center, Rochester, New York, 14642, United States |
| URL: | https://clinicaltrials.gov/show/NCT05153174 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|